Blastomycosis in Minnesota, USA, 1999–2018

Ireland, Malia; Klumb, Carrie; Smith, Kirk E.; Scheftel, Joni

doi:10.3201/eid2605.191074

Cited by 23 publications

(31 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the drug of choice will depend on the drug susceptibility report of the isolate. In our study, 83% of patients received echinocandins, while 13% of patients received azoles as per sensitivity report; meanwhile, in a study by Arensman et al, 92% of patients received echinocandins and 8% received azoles [ 21 ]. There is currently no evidence to support combination therapy in bloodstream infections with this organism, although if the urinary tract or CNS is involved dual therapy may be necessary [ 22 ].…”

Section: Discussionsupporting

confidence: 62%

International Multicentre Study of Candida auris Infections

Pandya¹,

Çağ

Pandak

et al. 2021

JoF

View full text Add to dashboard Cite

Background:Candida auris has emerged globally as a multi-drug resistant yeast and is commonly associated with nosocomial outbreaks in ICUs. Methods: We conducted a retrospective observational multicentre study to determine the epidemiology of C. auris infections, its management strategies, patient outcomes, and infection prevention and control practices across 10 centres from five countries. Results: Significant risk factors for C. auris infection include the age group of 61–70 years (39%), recent history of ICU admission (63%), diabetes (63%), renal failure (52%), presence of CVC (91%) and previous history of antibiotic treatment (96%). C. auris was commonly isolated from blood (76%). Echinocandins were the most sensitive drugs. Most common antifungals used for treatment were caspofungin (40%), anidulafungin (28%) and micafungin (15%). The median duration of treatment was 20 days. Source removal was conductedin 74% patients. All-cause crude mortality rate after 30 days was 37%. Antifungal therapy was associated with a reduction in mortality (OR:0.27) and so was source removal (OR:0.74). Contact isolation precautions were followed in 87% patients. Conclusions:C. auris infection carries a high risk for associated mortality. The organism is mainly resistant to most azoles and even amphotericin-B. Targeted antifungal therapy, mainly an echinocandin, and source control are the prominent therapeutic approaches.

show abstract

Section: Discussionsupporting

confidence: 62%

International Multicentre Study of Candida auris Infections

Pandya¹,

Çağ

Pandak

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…Data about environmental exposures, immunocompromised status, body site of infection, occupation, illness duration, and treatment were not available consistently from every state. Wisconsin and Minnesota conducted extensive follow-up on cases ( 19 , 25 ), providing deeper insight into state-specific features of blastomycosis. Collecting these types of data in a standardized way in additional states could help identify high-risk populations and activities and help inform prevention efforts.…”

Section: Discussionmentioning

confidence: 99%

Blastomycosis Surveillance in 5 States, United States, 1987–2018

Benedict¹,

Gibbons-Burgener²,

Kocharian³

et al. 2021

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

“…We observed an overall mortality rate of 16.2% in this study cohort, which is higher than the mortality rate observed in recently published large cohorts. A US nationwide study found an overall in-hospital mortality rate of 6.9% (18), and an overall case-fatality rate in a cohort of 671 cases in Minnesota during 1999-2018 was 10% (19). In a systematic review and meta-analysis, the mortality estimate for general clinical cases of blastomycosis was 6.6% overall (20); substantial heterogeneity between the included studies was mainly attributed to inconsistent definitions of mortality.…”

Section: Discussionmentioning

confidence: 99%

Changing Patterns of Disease Severity in Blastomyces dermatitidis Infection, Quebec, Canada

Carignan¹,

Boudhrioua²,

Moreira³

et al. 2021

Emerg. Infect. Dis.

View full text Add to dashboard Cite

B lastomyces dermatitidis, a dimorphic fungus, causes a localized or disseminated pyogranulomatous fungal infection called blastomycosis. Various descriptive studies have shown predominantly pulmonary, skin, bone, and genitourinary involvement (1). The clinical spectrum of blastomycosis is wide, ranging from subclinical infection to critical cases of acute respiratory distress syndrome. Retrospective studies conducted in recent years have shown an increased incidence of blastomycosis in both Canada and the United States (2-5). Blastomycosis is endemic to the St. Lawrence River Valley; a study that focused on the incidence of blastomycosis in the province of Quebec, Canada (6), showed an increasing incidence from 1988 to 2011. Similar trends have been observed in several regions in the United States (7), although the underlying causes are poorly understood. The absence of robust reporting and lack of reportability in many jurisdictions may hamper the ability to know whether cases are increasing more broadly. Some authors suggested a possible relationship with certain climatic factors (3,8). In the wake of the increased incidence of blastomycosis in Quebec, clinicians have observed a possible worsening of the disease severity in patients, with occasional deaths.This study aimed to assess temporal changes in the severity and mortality of blastomycosis in Quebec and to identify risk factors for blastomycosis-related deaths. In Quebec, all suspected B. dermatitidis isolates are sent for molecular species confi rmation at

show abstract

Blastomycosis in Minnesota, USA, 1999–2018

Cited by 23 publications

References 30 publications

International Multicentre Study of Candida auris Infections

International Multicentre Study of Candida auris Infections

Blastomycosis Surveillance in 5 States, United States, 1987–2018

Changing Patterns of Disease Severity in Blastomyces dermatitidis Infection, Quebec, Canada

Contact Info

Product

Resources

About